Advancements in Treating Psychiatric Disorders With Psilocybin
April 23, 2024 DOI: 10.64239/pi-qt6202 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Topics | Psilocybin |
| Key findings | Psilocybin shows promise for treatment-resistant depression, but its efficacy without concurrent psychotherapy and its long-term safety risks remain uncertain. |
Abstract
Psilocybin shows promise for treatment-resistant depression, with rapid onset and long-lasting effects. Psilocybin treatment currently involves extensive psychotherapy sessions, which may limit accessibility and increase costs. The efficacy of psilocybin without concurrent psychotherapy is unknown. Long-term safety risks of psilocybin treatment remain uncertain.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |